Journal Article Review Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural Ppublish 25 citations
PubMed: 35534356 DOI: 10.1016/j.tips.2022.04.002
Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.
Trends Pharmacol Sci 43(8):686-700
Authors: Lizhi Pang, Fatima Khan, Madeline Dunterman, Peiwen Chen
Affiliations
- Department of Neurological Surgery, Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
- Department of Neurological Surgery, Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Abstract
Glioblastoma (GBM) is the most common and highly lethal form of primary brain tumor in adults. The median survival of GBM patients is approximately 14-16 months despite multimodal therapies. Emerging evidence has substantiated the critical role of symbiotic interactions between GBM cells and noncancerous immune cells (e.g., myeloid cells and T cells) in regulating tumor progression and therapy resistance. Approaches to target the tumor-immune symbiosis have emerged as a promising therapeutic strategy for GBM. Here, we review the recent developments for pharmacological targeting of the GBM-immune symbiosis and highlight the role of such strategies to improve the effectiveness of immunotherapies in GBM.
MeSH
Glioblastoma, Macrophages, Immunotherapy, Cells, Therapeutics, Neoplasms, Symbiosis
Cited by
- Microglia and Brain Macrophages as Drivers of Glioma Progression. Int J Mol Sci, 2022
- Epigenetic regulation of tumor-immune symbiosis in glioma. Trends Mol Med, 2024
- Targeting legumain-mediated cell-cell interaction sensitizes glioblastoma to immunotherapy in preclinical models. J Clin Invest, 2025
- Protease regulation of tumor-immune cell symbiosis. Trends Cancer, 2025
- Lipid-Laden Macrophages Recycle Myelin to Feed Glioblastoma. Cancer Res, 2024
- The benefits of rehabilitation exercise in improving chronic traumatic encephalopathy: recent advances and future perspectives. Mol Med, 2023
- Causal inference between immune cells and glioblastoma: a bidirectional Mendelian randomization study. J Cancer, 2025
- Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J Clin Invest, 2023
- Interactions between glioblastoma and myeloid cells. Front Cell Dev Biol, 2025
- Evaluation of in-vivo and in-vitro binding property of a novel PET tracer for CSF1R imaging and comparison with two currently-used CSF1R-PET tracers. Res Sq, 2025
- Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma. Cell Rep Med, 2023
- Glycoprotein NMB mediates bidirectional GSC-TAM interactions to promote tumor progression. JCI Insight, 2025
- LDHA-regulated tumor-macrophage symbiosis promotes glioblastoma progression. Res Sq, 2023
- Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Commun (Lond), 2023
- Therapeutic potential of targeting macrophages and microglia in glioblastoma. Trends Pharmacol Sci, 2025
- Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma. J Clin Invest, 2024
- Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol, 2024
- Epigenetic regulation of tumor immunity. J Clin Invest, 2024
- Evaluation of in vivo and in vitro binding property of a novel candidate PET tracer for CSF1R imaging and comparison with two currently-used CSF1R-PET tracers. EJNMMI Radiopharm Chem, 2025
- Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma. Nat Immunol, 2023